The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy.
about
Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum womenGoldilocks' Determination of What New In Vivo Data are "Just Right" for Different Common Drug Development Scenarios, Part 1.Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome.Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient MiceTherapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy.Nonclinical aspects of venous thrombosis in pregnancy.Gestation age dependent transfer of human immunoglobulins across placenta in timed-pregnant guinea pigs.An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.Changes of MAO-A and MAO-B Expressions in the Placenta of MPTP or MPP(+) Treated Mice.Transfer of maternal immunity and programming of the newborn immune system.Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypesPlacental transfer of a fully human IgG2 monoclonal antibody in the cynomolgus monkey, rat, and rabbit: a comparative assessment from during organogenesis to late gestation.Placental transfer of Fc-containing biopharmaceuticals across species, an industry survey analysis.FcRn Expression on Placenta and Fetal Jejunum during Early, Mid-, and Late Gestation in Minipigs.An Enhanced Pre- and Postnatal Development Study in Cynomolgus Monkeys with Tabalumab: A Human IgG4 Monoclonal Antibody.Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques.
P2860
Q28394815-52B8DB82-C129-4AB3-A0D4-FE8F9F6A2C20Q31127064-7C8A059C-8BBB-4148-BF27-CB47FCD3CDA2Q34081859-42424F7F-E775-49CE-BD79-F06A0309CE7CQ36060983-C52103F0-9AC9-40C4-9E91-385A79EB27DEQ38555085-06C6541B-B920-4C1E-B98E-8AF5A1FD5F6AQ38592536-ACFF942F-F626-4D02-9DC1-8657A065A267Q38636441-9C2B338F-AFFB-462B-ABB2-DB505DF6EF1DQ38803301-C97FDA91-FA92-47AE-B2D9-AAA5E32642D3Q39688860-3FDDCFE3-CC59-419A-9901-51D2CF5DA67AQ41991852-ADA5462C-4B74-4FDE-8463-CA8B4D327CA4Q42366290-A1E51912-CF51-40BD-9162-6788AFFFE268Q43534415-5AFF8645-E0C6-45E6-B6F9-077388450BAFQ43583667-C64AF1D1-E956-45A8-B250-DAF7A2EA1DB0Q46646640-F4053E71-B302-4787-895C-D6D37944A2F6Q50576879-2DE3598F-49F2-4562-A5C6-1404355A9F6DQ54558643-6021A0D8-2ADF-4EA6-B005-EEC68E31FE63
P2860
The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The placenta, transfer of immu ...... opharmaceuticals in pregnancy.
@en
The placenta, transfer of immu ...... opharmaceuticals in pregnancy.
@nl
type
label
The placenta, transfer of immu ...... opharmaceuticals in pregnancy.
@en
The placenta, transfer of immu ...... opharmaceuticals in pregnancy.
@nl
prefLabel
The placenta, transfer of immu ...... opharmaceuticals in pregnancy.
@en
The placenta, transfer of immu ...... opharmaceuticals in pregnancy.
@nl
P2093
P2860
P1476
The placenta, transfer of immu ...... iopharmaceuticals in pregnancy
@en
P2093
Amy L Williams
Arshiya Ahuja
John M DeSesso
Mark E Hurtt
P2860
P304
P356
10.3109/10408444.2011.653487
P407
P50
P577
2012-03-01T00:00:00Z